GSK Gets EU Approval for Expanded Use of Nucala in COPD

Key Takeaways GSK's Nucala gained EU nod as an add-on maintenance treatment for certain COPD patients.Phase III MATINEE data showed Nucala reduced moderate/severe COPD exacerbations versus placebo.GSK's Nucala is the first and only biologic in the EU for COPD patients with an eosinophilic phenotype.GSK plc (GSK) announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for treating certain patients with chronic obstructive pulmonary disease (COPD), marking a ...